Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.07), Zacks reports.
Fulcrum Therapeutics Trading Down 1.6%
Shares of NASDAQ:FULC opened at $3.68 on Friday. The firm’s 50 day moving average price is $3.74 and its 200-day moving average price is $5.59. Fulcrum Therapeutics has a twelve month low of $2.83 and a twelve month high of $15.74.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating, seven have issued a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average price target of $8.20.
View Our Latest Research Report on FULC
About Fulcrum Therapeutics
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It develops medicines for genetically defined diseases, with research focused on changing gene expression to address the underlying causes of illness. The company’s work has included programs for sickle cell disease and facioscapulohumeral muscular dystrophy, a rare genetic muscle disorder. Its research has explored approaches such as influencing hemoglobin production and modifying disease-related gene activity.
Featured Stories
- Five stocks we like better than Fulcrum Therapeutics
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
